100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43HL152819
Award Date
7/17/20
Completion Date
12/31/21
Dollars Obligated
$378K
Overview
Activity
3
Transactions
3
Subawards
Similar Awards
Federal Agency
National Heart Lung and Blood Institute
Awardee
Microvascular Therapeutics Inc. (ZA54X6LR5AS3)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Arizona, USA
Update #1
Update #2
ULTRASOUND-STIMULATED PHASE-CHANGE CONTRAST AGENTS FOR SONOTHROMBOLYSIS.
Posted 7/17/20
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
ULTRASOUND-STIMULATED PHASE-CHANGE CONTRAST AGENTS FOR SONOTHROMBOLYSIS. - ABSTRACT CARDIOVASCULAR DISEASE IS THE LEADING CAUSE OF DEATH AND DISABILITY WORLDWIDE ACCOUNTING FOR 840,678 DEATHS IN THE US IN 2016. ACUTE MYOCARDIAL INFARCTION CAUSED BY THROMBUS WITHIN THE CORONARY ARTERIES IS THE MAJOR CULPRIT IN CARDIOVASCULAR DISEASE. ST-ELEVATION MYOCARDIAL INFARCTION (STEMI), RESULTS IN DEATH AND DISABILITY DUE TO DAMAGE TO CARDIAC MYOCYTES AND DECREASED CARDIAC FUNCTION. DESPITE ADVANCEMENTS IN RESTORING EPICARDIAL ARTERY PATENCY VIA REPERFUSION THERAPY, MICROVASCULAR OBSTRUCTION (MVO) LIMITS CARDIOVASCULAR RECOVERY AT THE TISSUE LEVEL AND RESULTS IN POORER PROGNOSIS, INCLUDING DEATH. WHILE THE PREVALENCE OF MVO RANGES FROM 10% TO >70%, THERE IS NO CONSENSUS ON HOW TO SAFELY AND EFFECTIVELY PREVENT OR TREAT MVO. EFFORTS TO REMOVE OCCLUSIVE THROMBI VIA THROMBECTOMY, MECHANICAL DISRUPTION, AND/OR BIOCHEMICAL DISSOLUTION HAVE DEMONSTRATED EFFICACY; HOWEVER, THESE ARE TIME CONSUMING, SHOW MIXED RESULTS IN IMPROVING CLINICAL OUTCOMES, AND ARE ACCOMPANIED BY SUBSTANTIAL RISK OF HEMORRHAGIC COMPLICATIONS. EFFORTS TO ENHANCE THE SAFETY AND EFFICACY OF THROMBUS REMOVAL HAVE HIGH POTENTIAL CLINICAL IMPACT. ULTRASOUND HAS BEEN SHOWN TO DISRUPT THROMBI AND MICROBUBBLES (MB) CAN LOCALLY AMPLIFY AND ACCELERATE ULTRASOUND-ENHANCED THROMBOLYSIS AT A LOWER ENERGY LEVEL. A CAVEAT TO THE USE OF MBS STEMS FROM THEIR SIZE (1-3 MICRONS), WHICH MAY LIMIT THEIR ACCESS TO THE INTERIOR OF THE MICROTHROMBI RESPONSIBLE FOR MVO. SMALLER ACOUSTICALLY ACTIVE MATERIALS, INCLUDING PHASE CHANGE NANODROPLETS (ND, ~100- 200 NM), SHOULD MORE EASILY PENETRATE THROMBUS TO INCREASE SONOTHROMBOLYTIC EFFICIENCY AND CLINICAL EFFICACY. MICROVASCULAR THERAPEUTICS (MVT) HAS DEVELOPED A SAFE AND MORE STABLE LIPID-BASED MB (MVT-100) LESS LIKELY TO INDUCE ANAPHYLACTOID REACTIONS AS COMPARED TO DEFINITY AND IS DEVELOPING MVT-100 VIA THE 505(B)(2) PATHWAY. MOREOVER, MVT HAS SUBSEQUENTLY MADE ND FROM MVT-100 (PATENT, US 9,427,410B2) AND CONJUGATED ND WITH A PEPTIDE LIGAND WITH HIGH AFFINITY FOR FIBRIN (FTND). ELECTRON MICROSCOPY OF FIBRIN CLOTS SHOWS THAT THAT FTND PERMEATE CLOT > NON-TARGETED ND >> MB. PRELIMINARY STUDIES PERFORMED IN OUR LABORATORY AS WELL AS BY OUR COLLABORATORS AT THE UNIVERSITY OF PITTSBURGH CENTER FOR ULTRASOUND MOLECULAR IMAGING AND THERAPEUTICS IN AN IN VITRO MODEL OF MVO SHOW THAT FIBRIN MICRO-CLOTS ARE DISRUPTED BY US WITH ND >> MB. IN THIS PHASE I SBIR, OUR COMBINED GROUPS PROPOSE TO CHARACTERIZE FIBRIN TARGETED NDS (FTND) AND EVALUATE THEIR EFFECTIVENESS IN VIVO IN DISRUPTING THE MICROVASCULAR THROMBI IN A BIOLOGICALLY RELEVANT MODEL REFLECTIVE OF MVO DURING ACUTE MYOCARDIAL INFARCTION. AFTER PRODUCTION OF BIOCONJUGATE AND FTNDS, WE WILL EVALUATE THEIR BINDING TO THE FIBRIN TARGET. WE HYPOTHESIZE THAT FTND WILL IMPROVE FIBRIN CLOT DETECTION AND ACHIEVE SUPERIOR DISSOLUTION OF THROMBI UPON ULTRASOUND ACTIVATION AS COMPARED TO MBS. THE OVERALL GOAL OF THIS PHASE I PROGRAM IS TO OBTAIN PROOF OF CONCEPT FOR THE USAGE OF FTNDS AND PERFORM FEASIBILITY STUDIES WHICH WILL IF SUCCESSFUL, SUPPORT FURTHER PRECLINICAL DEVELOPMENT AND IND-ENABLING STUDIES OF ND FOR A PHASE II SBIR GRANT APPLICATION IN STEMI.
$0
7/1/22
Not listed
ULTRASOUND-STIMULATED PHASE-CHANGE CONTRAST AGENTS FOR SONOTHROMBOLYSIS. - ABSTRACT CARDIOVASCULAR DISEASE IS THE LEADING CAUSE OF DEATH AND DISABILITY WORLDWIDE ACCOUNTING FOR 840,678 DEATHS IN THE US IN 2016. ACUTE MYOCARDIAL INFARCTION CAUSED BY THROMBUS WITHIN THE CORONARY ARTERIES IS THE MAJOR CULPRIT IN CARDIOVASCULAR DISEASE. ST-ELEVATION MYOCARDIAL INFARCTION (STEMI), RESULTS IN DEATH AND DISABILITY DUE TO DAMAGE TO CARDIAC MYOCYTES AND DECREASED CARDIAC FUNCTION. DESPITE ADVANCEMENTS IN RESTORING EPICARDIAL ARTERY PATENCY VIA REPERFUSION THERAPY, MICROVASCULAR OBSTRUCTION (MVO) LIMITS CARDIOVASCULAR RECOVERY AT THE TISSUE LEVEL AND RESULTS IN POORER PROGNOSIS, INCLUDING DEATH. WHILE THE PREVALENCE OF MVO RANGES FROM 10% TO >70%, THERE IS NO CONSENSUS ON HOW TO SAFELY AND EFFECTIVELY PREVENT OR TREAT MVO. EFFORTS TO REMOVE OCCLUSIVE THROMBI VIA THROMBECTOMY, MECHANICAL DISRUPTION, AND/OR BIOCHEMICAL DISSOLUTION HAVE DEMONSTRATED EFFICACY; HOWEVER, THESE ARE TIME CONSUMING, SHOW MIXED RESULTS IN IMPROVING CLINICAL OUTCOMES, AND ARE ACCOMPANIED BY SUBSTANTIAL RISK OF HEMORRHAGIC COMPLICATIONS. EFFORTS TO ENHANCE THE SAFETY AND EFFICACY OF THROMBUS REMOVAL HAVE HIGH POTENTIAL CLINICAL IMPACT. ULTRASOUND HAS BEEN SHOWN TO DISRUPT THROMBI AND MICROBUBBLES (MB) CAN LOCALLY AMPLIFY AND ACCELERATE ULTRASOUND-ENHANCED THROMBOLYSIS AT A LOWER ENERGY LEVEL. A CAVEAT TO THE USE OF MBS STEMS FROM THEIR SIZE (1-3 MICRONS), WHICH MAY LIMIT THEIR ACCESS TO THE INTERIOR OF THE MICROTHROMBI RESPONSIBLE FOR MVO. SMALLER ACOUSTICALLY ACTIVE MATERIALS, INCLUDING PHASE CHANGE NANODROPLETS (ND, ~100- 200 NM), SHOULD MORE EASILY PENETRATE THROMBUS TO INCREASE SONOTHROMBOLYTIC EFFICIENCY AND CLINICAL EFFICACY. MICROVASCULAR THERAPEUTICS (MVT) HAS DEVELOPED A SAFE AND MORE STABLE LIPID-BASED MB (MVT-100) LESS LIKELY TO INDUCE ANAPHYLACTOID REACTIONS AS COMPARED TO DEFINITY AND IS DEVELOPING MVT-100 VIA THE 505(B)(2) PATHWAY. MOREOVER, MVT HAS SUBSEQUENTLY MADE ND FROM MVT-100 (PATENT, US 9,427,410B2) AND CONJUGATED ND WITH A PEPTIDE LIGAND WITH HIGH AFFINITY FOR FIBRIN (FTND). ELECTRON MICROSCOPY OF FIBRIN CLOTS SHOWS THAT THAT FTND PERMEATE CLOT > NON-TARGETED ND >> MB. PRELIMINARY STUDIES PERFORMED IN OUR LABORATORY AS WELL AS BY OUR COLLABORATORS AT THE UNIVERSITY OF PITTSBURGH CENTER FOR ULTRASOUND MOLECULAR IMAGING AND THERAPEUTICS IN AN IN VITRO MODEL OF MVO SHOW THAT FIBRIN MICRO-CLOTS ARE DISRUPTED BY US WITH ND >> MB. IN THIS PHASE I SBIR, OUR COMBINED GROUPS PROPOSE TO CHARACTERIZE FIBRIN TARGETED NDS (FTND) AND EVALUATE THEIR EFFECTIVENESS IN VIVO IN DISRUPTING THE MICROVASCULAR THROMBI IN A BIOLOGICALLY RELEVANT MODEL REFLECTIVE OF MVO DURING ACUTE MYOCARDIAL INFARCTION. AFTER PRODUCTION OF BIOCONJUGATE AND FTNDS, WE WILL EVALUATE THEIR BINDING TO THE FIBRIN TARGET. WE HYPOTHESIZE THAT FTND WILL IMPROVE FIBRIN CLOT DETECTION AND ACHIEVE SUPERIOR DISSOLUTION OF THROMBI UPON ULTRASOUND ACTIVATION AS COMPARED TO MBS. THE OVERALL GOAL OF THIS PHASE I PROGRAM IS TO OBTAIN PROOF OF CONCEPT FOR THE USAGE OF FTNDS AND PERFORM FEASIBILITY STUDIES WHICH WILL IF SUCCESSFUL, SUPPORT FURTHER PRECLINICAL DEVELOPMENT AND IND-ENABLING STUDIES OF ND FOR A PHASE II SBIR GRANT APPLICATION IN STEMI.
$0
7/1/22
Not listed
ULTRASOUND-STIMULATED PHASE-CHANGE CONTRAST AGENTS FOR SONOTHROMBOLYSIS.
$378.2k
7/17/20